Mechanism of Action
NK1 Receptor Signaling
Substance P binds NK1 receptors (Gq-coupled GPCRs) on spinal dorsal horn neurons, activating phospholipase C, raising IP3 and diacylglycerol, and increasing intracellular calcium. This potentiates NMDA receptor activity and contributes to wind-up and central sensitization of pain processing. NK1 receptors in the nucleus tractus solitarius and area postrema mediate the emetic reflex, explaining substance P's role in nausea and vomiting.
Neurogenic Inflammation
Peripheral release of substance P from C-fiber terminals causes vasodilation, plasma extravasation, and mast cell degranulation -- the cardinal features of neurogenic inflammation. This mechanism underlies conditions like neurogenic cystitis, migraine-associated meningeal inflammation, and rosacea flares. Substance P also activates immune cells (macrophages, lymphocytes) expressing NK1 receptors, linking the nervous and immune systems in inflammatory conditions.
Research Summary
Pain and Central Sensitization
Well EstablishedIntrathecal substance P produces hyperalgesia in animals. NK1 receptor knockout mice show impaired pain responses and reduced central sensitization. Elevated substance P in CSF is found in fibromyalgia, IBS, and chronic pain conditions. NK1 antagonists reduce central sensitization in preclinical models, though direct analgesic efficacy in humans has been modest compared to the strong preclinical data.
Chemotherapy-Induced Nausea (NK1 Antagonists)
Clinical ValidationNK1 receptor antagonists aprepitant and netupitant are FDA-approved for prevention of chemotherapy-induced nausea and vomiting (CINV), validating substance P's emetic role. Combined with 5-HT3 antagonists and dexamethasone, NK1 antagonists provide superior protection against delayed-phase CINV. This clinical success indirectly confirms substance P biology.
Depression and Anxiety
Active ResearchNK1 antagonists show antidepressant effects in early clinical trials (Kramer et al., 1998: NK1 antagonist MK-0869 equivalent to paroxetine for major depression). Substance P is elevated in depression and stress. Interest in NK1 antagonism as novel antidepressant mechanism continues, with trials exploring tradipitant for depression, prurigo nodularis, and gastroparesis.
Calculate your Substance P dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pain/neurogenic inflammation research | 1-10 nmol/kg IV or intrathecal 0.1-1 nmol in rodents | Single dose per session | Intravenous or intrathecal |
| NK1 antagonist (aprepitant) CINV prevention | 125 mg day 1, 80 mg days 2-3 PO (clinical reference) | Three-day course with chemotherapy | Oral |
Exogenous substance P is primarily a research tool. Clinical applications target NK1 receptor blockade rather than substance P agonism.
Interactions
Safety Profile
Exogenous substance P IV causes transient flushing, hypotension, and pain at injection site due to mast cell activation and vasodilation. Intradermal injection produces the classic wheal-and-flare neurogenic inflammation response. Not used therapeutically as an agonist. NK1 antagonists (aprepitant) are well tolerated with primary adverse effects of fatigue and hiccups. No significant cardiotoxicity. Substance P itself as a research reagent requires careful dosing due to potent vascular and inflammatory effects.
References
- [1]von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol. 1931;72(1):74-87.
- [2]Kramer MS, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281(5383):1640-1645.
- [3]Hesketh PJ, et al. American Society of Clinical Oncology antiemetic guidelines. J Clin Oncol. 2017;35(28):3240-3261.